Location History:
- Oxfordshire, GB (2017 - 2020)
- Abingdon, GB (2016 - 2021)
Company Filing History:
Years Active: 2016-2021
Title: Chris Yarnold: Innovator in Thromboembolic Disease Treatment
Introduction
Chris Yarnold is a notable inventor based in Abingdon, GB. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds for the treatment of thromboembolic diseases. With a total of 6 patents to his name, Yarnold's work is recognized for its potential impact on medical therapies.
Latest Patents
Yarnold's latest patents include innovative compounds that serve as inhibitors of factor XIa. One of his notable inventions is titled "Substituted pyrrolidines as factor XIa inhibitors for the treatment of thromboembolic diseases." This invention provides compounds of a specific general formula, along with their salts, N-oxides, solvates, and prodrugs. These compounds are designed to be effective in preventing and treating thromboembolic diseases. Another significant patent is "Pyrimidinone and its derivatives inhibiting factor XIa," which similarly offers compounds that inhibit factor XIa, contributing to the prevention and therapy of thromboembolic conditions.
Career Highlights
Yarnold is currently associated with Ono Pharmaceutical Co., Ltd., where he continues to innovate and develop new therapeutic solutions. His work is characterized by a strong focus on creating effective treatments for serious health conditions.
Collaborations
Yarnold has collaborated with notable colleagues, including Steve Courtney and Stuart Flanagan. These partnerships have likely contributed to the advancement of his research and the successful development of his patents.
Conclusion
Chris Yarnold's contributions to the field of pharmaceuticals, particularly in the area of thromboembolic disease treatment, highlight his role as an influential inventor. His innovative patents and collaborations reflect his commitment to advancing medical science and improving patient outcomes.